南方财经3月9日电，云顶新耀（01952.HK）宣布，旗下自身免疫性疾病领域核心产品维适平®（精氨酸艾曲莫德片，VELSIPITY®）中国大陆首张处方于中山大学附属第一医院开出，标志着这款创新疗法正式进入中国临床应用阶段。
值得关注的是，维适平®于今年2月获得国家药监局批准上市，仅一个月便实现中国大陆首方落地，推进速度明显快于行业平均水平。业内认为，这不仅反映出该产品较高的临床需求，也体现了云顶新耀在创新药商业化方面的执行效率。据悉，该药物当日在广州、上海、杭州、西安、重庆、北京和南京7个核心城市的8家三甲医院同步开出处方，实现上市首日即覆盖全国重点区域患者，并通过互联网医院渠道进一步扩大患者覆盖范围。（21世纪经济报道）
（文章来源：南方财经网）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.